Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Treakisym Succeeds in PIII DLBCL Study, Japan Filing Eyed in H1 2020: SymBio
November 6, 2019
- Takeda to Divest Non-Core Assets Sold in Russia, Former Soviet States
November 6, 2019
- Daiichi Sankyo Sues Seattle Genetics over ADC Technology
November 6, 2019
- Eisai Transfers Tazemetostat Royalty Rights Outside Japan to US Firm
November 6, 2019
- Crysvita Accepted for Review in Europe for Additional Adult Use
November 6, 2019
- Torii Acquires Japan Marketing Rights to BioCryst’s HAE Treatment
November 6, 2019
- Boehringer Japan to Support Pharmacists and Nurses to Improve Treatment of COPD
November 5, 2019
- Boehringer Japan Aims to Maintain Top Combined COPD Market Share for LAMA/LABA Combos, LAMA Monodrugs
November 5, 2019
- Roivant Wants to Validate Its Biz Model with Commercial Success of Sumitomo Dainippon Alliance: CEO
November 5, 2019
- Hemlibra Now Available in Taiwan
November 5, 2019
- Bullish New Drugs Mitigated Vesicare/Tarceva Patent Cliff: Astellas CEO
November 1, 2019
- Daiichi Sankyo Ramps Up R&D Investment for ADC, 16 Studies Added to DS-8201
November 1, 2019
- Takeda’s Underlying Revenue Skids 0.2% in 1st Half as Rare Disease Biz Weighs
November 1, 2019
- Despite a Hold by Key Panel, Ono Sees Cachexia Drug Launch in April-September 2020
November 1, 2019
- Astellas, Pandion Link Arms on Pancreas-Targeted Immunomodulators
November 1, 2019
- Xtandi Helps Astellas Counter Vesicare/Tarceva LOEs in April-September
November 1, 2019
- Edoxaban Drives Daiichi Sankyo’s Half-Year Earnings
November 1, 2019
- Satralizumab Accepted for Review in Europe, US; Chugai Plans Japan Filing Before Year-End
November 1, 2019
- Sumitomo, Roivant Ink Definitive Alliance Deal; Ex-Genentech Exec to Wield Baton
November 1, 2019
- Ono Checks In 3.2% Revenue Growth on Opdivo, Forxiga in 1st Half
November 1, 2019
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…